Can high omega-6 load, CD36 uptake genetics, and fat malabsorption keep EPA low despite supplementation?

Systemic eicosapentaenoic acid (EPA) levels are regulated by a complex interplay of dietary intake, intestinal absorption efficiency, and enzymatic competition. When patients fail to see expected increases in systemic EPA despite oral supplementation, several distinct physiological barriers may be responsible.

Absorption and genetic barriers

• Intestinal uptake genetics: The A allele of the CD36 translocase gene (rs1761667 AA genotype) is robustly associated with reduced promoter activity and lower CD36 expression. Experimental models demonstrate that downregulated CD36 expression decreases intestinal lipid uptake and increases fecal fat excretion, indicating that this genetic variant can plausibly limit the bioavailability of oral EPA.
• Fat malabsorption: Generalized fat malabsorption presents a major physiological barrier. Because EPA is a long-chain fatty acid, clinical conditions that impair overall lipid digestion and absorption will directly impede the uptake of supplemental omega-3s.

Biochemical competition and metabolic bypass

• Omega-6 substrate competition: A high dietary omega-6 substrate load competes directly with omega-3 fatty acids for shared metabolizing enzymes, such as FADS1. This biochemically well-established competition can restrict the accumulation of systemic EPA.
• FADS1 conversion bypass: Attributing poor supplementation response to FADS1 rs174547 TT conversion limitations is incorrect. The minor C allele (CC genotype), not the TT genotype, is the variant associated with reduced desaturase activity. Furthermore, direct supplementation with preformed EPA bypasses this upstream enzymatic bottleneck entirely.

Bottom line

• While fat malabsorption, CD36 genetic uptake variants (rs1761667 AA), and high omega-6 competition can plausibly restrict oral EPA bioavailability, FADS1 conversion limitations do not hinder the efficacy of direct EPA supplementation because preformed EPA bypasses this metabolic bottleneck.